Phase 1 Study of KB407 Green-lighted in Australia

Phase 1 Study of KB407 Green-lighted in Australia

307713

Phase 1 Study of KB407 Green-lighted in Australia

A research ethics committee in Australia has given Krystal Biotech the go-ahead to start a Phase 1 clinical study of KB407, the company’s investigational inhaled gene therapy for cystic fibrosis (CF). Enrollment for the trial is expected to start soon, according to Krystal, following approval from the institutional governance and biosafety committee at the site of the trial (not yet specified). Krystal is also planning to start a trial in the U.S. soon. “While COVID…

You must be logged in to read/download the full post.